Brought to you by 
Concert Pharmaceuticals closes $10mm Series A round
28 Feb 2013
Executive Summary
Concert Pharmaceuticals (small-molecule therapeutics) has raised $10mm in its Series A financing round co-led by Three Arch Partners, TVM Capital, and Skyline Ventures with additional participation from Greylock Partners and QVT Fund.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Concert Pharmaceuticals closes $10mm Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice